HAC (Russian)
RSCI (Russian)
EBSCO
DOI (USA)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Efficacy of venlafaxine in chronic pain syndrome

DOI: https://doi.org/10.29296/25877305-2019-04-06
Issue: 
4
Year: 
2019

T. Vazagaeva, Candidate of Medical Sciences; E. Kvariantashvili V.P. Serbsky National Medical Research Center of Psychiatry and Narcology. Moscow

Along with analgesics, adjuvant medications are currently recommended for the treatment of various chronic pain syndromes. The antidepressants with proven analgesic effects include venlafaxine that has a more favorable tolerability profile than tricyclic antidepressants traditionally used to treat patients with chronic pain. Many studies have shown that venlafaxine is highly effective in the therapy of neuropathic pain, while the efficacy of the drug for other types of chronic pain has not been studied sufficiently. Although most current guidelines do not consider venlafaxine as a first-line drug treatment for chronic pain, there are grounds for its use in clinical practice in many cases, for example, those with poor tolerance or contraindications to other antidepressants and anticonvulsants. Further investigations are necessary for more and additional information about the features and spectrum of the analgesic activity of venlafaxine

Keywords: 
therapy
chronic pain syndrome
venlafaxine



References: 
  1. Goldberg D., McGee S. Pain as a global public health priority // BMC Public Health. – 2011; 11: 770. DOI: 10.1186/1471-2458-11-770.
  2. Rice A., Smith B., Blyth F. Pain and the global burden of disease // Pain. – 2016; 157 (4): 791–6. DOI: 10.1097/j.pain.0000000000000454.
  3. Finnerup N., Scholz J., Attal N. et al. Neuropathic pain needs systematic classification // Eur. J. Pain. – 2013; 17: 953–6. DOI: 10.1002/j.1532-2149.2012.00282.x.
  4. Rief W., Kaasa S., Jensen R.et al. The need to revise pain diagnoses in ICD-11 // Pain. – 2010; 149: 169–70. DOI: 10.1016/j.pain.2010.03.006.
  5. Treede R., Rief W., Barke A. et al. A classification of chronic pain for ICD-11 // Pain. – 2015; 156 (6): 1003–7. DOI: 10.1097/j.pain.0000000000000160.
  6. Treede R., Rief W., Barke A.et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11) // Pain. – 2019; 160 (1): 19–27. DOI: 10.1097/j.pain.0000000000001384.
  7. Nicholas M., Vlaeyen J., Rief W. et al. The IASP Taskforce for the Classification of Chronic pain. The IASP classification of chronic pain for ICD-11: chronic primary pain // Pain. – 2019; 160: 28–37. DOI: 10.1097/j.pain.0000000000001390.
  8. Khouzam H. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics // Postgrad Med. – 2016; 128 (3): 323–30. DOI: 10.1080/00325481.2016.1147925.
  9. Jann M., Slade J. Antidepressant agents for the treatment of chronic pain and depression // Pharmacotherapy. – 2007; 27: 1571–87. DOI: 10.1592/phco.27.11.1571.
  10. Katzman M., Pawluk E., Tsirgielis D. et al. Beyond chronic pain: how best to treat psychological comorbidities // J. Fam. Pract. – 2014; 63: 260–4.
  11. Rico-Villademoros F., Slim M., Calandre E. Amitriptyline for the treatment of fibromyalgia: a comprehensive review // Expert Rev. Neurother. – 2015; 15: 1123–50. DOI: 10.1586/14737175.2015.
  12. Shultz E., Malone D. Jr. A practical approach to prescribing antidepressants // Cleve Clin. J. Med. – 2013; 80: 625–31. DOI: 10.3949/ccjm.80a.
  13. Saarto T., Wiffen P. Antidepressants for neuropathic pain // Cochrane Database Syst. Rev. – 2005; 3: CD005454. DOI: 10.1002/14651858.CD005454.pub2.
  14. Gershon M., Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders // Gastroenterology. – 2007; 132: 397–414. DOI: 10.1053/j.gastro.2006.11.002.
  15. Makarov S.A., Churjukanov M.V., Churjukanov V.V. Antidepressanty v lechenii boli // Ross. zhurn. boli. – 2016; 3–4 (51): 74–85 [Makarov S.A., Churukanov M.V., Churukanov V.V. Antidepressants in the treatment of pain // Ross. zhurn. boli. – 2016; 3–4 (51): 74–85 (in Russ.)].
  16. Miura N., Saito T., Taira T. et al. Risk factors for QT prolongation associated with acute psychotropic drug overdose // Am. J. Emerg. Med. – 2015; 33: 142–9. DOI: 10.1016/j.ajem.2014.09.048.
  17. Rintala D., Holmes S., Courtade D. et al. Comparison of the effectiveness of amitriptyline and gabapentin in chronic neuropathic pain in persons with spinal cord injury // Arch. Phys. Med. Rehabil. – 2007; 88: 1547–60. DOI: 10.1016/j.apmr.2007.07.038.
  18. Sultana J., Spina E., Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety // Expert. Opin. Drug Metab. Toxicol. – 2015; 11: 883–92. DOI: 10.1517/17425255.2015.1021684.
  19. Rodieux F., Piguet V., Berney P. et al. Prescription of antidepressants in the treatment of pain: role of pharmacogenetics // Rev. Med. Suisse. – 2015; 11: 1374–9.
  20. Tack J., Broekaert D., Fischler B. et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome // Gut. – 2006; 55: 1095–103. DOI: 10.1136/gut.2005.077503.
  21. Avedisova A.S. Venlafaksin (velaksin): rezul'taty mezhdunarodnyh issledovanij antidepressanta III pokolenija // Psihiat. i psihofarmakoter. – 2006; 11 (2): 2–7 [Avedisova A.S. Venlafaksin (velaksin): rezul'taty mezhdunarodnykh issledovanii antidepressanta III pokoleniya // Psikhiatr. i psikhofarmakoter. – 2006; 11 (2): 2–7 (in Russ.)].
  22. Vazagaeva T.I., Fedorova A.I. Primenenie venlafaksina pri lechenii komorbidnyh depressivnyh i trevozhnyh rasstrojstv // Sots. i klin. psihiatr. – 2017; 27 (4): 47–52 [Vazagayeva T.I., Fedorova A.I. Venlafaxine in the treatment of comorbid depressive and anxious disorders // Sots. i klin. psikhiatr. – 2017; 27 (4): 47–52 (in Russ.)].
  23. Trouvin A., Perrot S., Lloret-Linares C. Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment // Clin. Ther. – 2017; 39 (6): 1104–22. DOI: 10.1016/j.clinthera.2017.05.347.
  24. Hughes S., Hickey L., Donaldson L. et al. Intrathecal Reboxetine Suppresses Evokedand Ongoing Neuropathic Pain Behaviours by Restoring Spinal Noradrenergic Inhibitory Tone // Pain. – 2015; 156: 328–34. DOI: 10.1097/01.j.pain.0000460313.73358.31.
  25. Hajhashemi V., Banafshe H., Minaiyan M. et al. Antinociceptive Effects of Venlafaxine in a Rat Model of Peripheral Neuropathy: Role of alpha 2-Adrenergic Receptors // Eur. J. Pharmacol. – 2014; 738: 230–6. DOI: 10.1016/j.ejphar.2014.04.046.
  26. Schreiber S., Backer M., Pick C. Theantinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms // Neurosci Lett. – 1999; 273 (2): 85–8.
  27. Cegielska-Perun, K., Bujalska-Zadrożny, M., Tatarkiewicz, J. et al. Venlafaxine and neuropathic pain // Pharmacology. – 2013; 91: 69–76. DOI: 10.1159/000345035.
  28. Bohren Y., Tessier L., Megat S. et al. Antidepressants Suppress Neuropathic Pain by a Peripheral β2-Adrenoceptor Mediated Anti-TNFα Mechanism // Neurobiol. Dis. – 2013; 60: 39–50. DOI: 10.1016/j.nbd.2013.08.012.
  29. Lelic D., Fischer I., Olesen A. et al. Venlafaxine and oxycodone effects on human spinal and supraspinal pain processing: a randomized cross-over trial // Eur. J. Neurosci. – 2016; 44 (11): 2966–74. DOI: 10.1111/ejn.13443.
  30. Lelic D., Valeriani M., Fischer I. et al. Venlafaxine and oxycodone have different effects on spinal and supraspinal activity in man: a somatosensory evoked potential study // Br. J. Clin. Pharmacol. – 2017; 83 (4): 764–76. DOI: 10.1111/bcp.13177.
  31. Aiyer R., Barkin R., Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review // Pain Med. – 2017; 18 (10): 1999–2012. DOI: 10.1093/pm/pnw261.
  32. Rowbotham M., Goli V., Kunz N. et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study // Pain. – 2004; 110 (3): 697–706. Erratum in: Pain. – 2005; 113 (1–2): 248. DOI: 10.1016/j.pain.2004.05.010.
  33. Jia H., Li Q., Song D. et al. Effects of Venlafaxine and Carbamazepine for Painful Peripheral Diabetic Neuropathy: A Randomized, Double-Blind and Double-Dummy, Controlled Multi-Center Trial // Chin. J. Evid-Based Med. – 2006; 6: 321–8.
  34. Razazian N., Baziyar M., Moradian N. et al. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial // Neurosciences (Riyadh). – 2014; 19 (3): 192–8.
  35. Simpson D. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy // J. Clin. Neuromuscul. Dis. – 2001; 3 (2): 53–62.
  36. Kadiroglu A., Sit D., Kayabasi H. et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus // J. Diabetes Complications. – 2008; 22 (4): 241–5. DOI: 10.1016/j.jdiacomp.2007.03.010. DOI:10.1016/j.jdiacomp.2007.03.010.
  37. Tasmuth T., Härtel B., Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer // Eur. J. Pain. – 2002; 6 (1): 17–24. DOI: 10.1053/eujp.2001.0266.
  38. Amr Y., Yousef A. Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain // Clin. J. Pain. – 2010; 26 (5): 381–5. DOI: 10.1097/AJP.0b013e3181cb406e.
  39. Reuben S., Makari-Judson G., Lurie S. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomypainsyndrome // J. Pain Symptom Manage. – 2004; 27 (2): 133–9. Retraction in: J. Pain Symptom Manage. – 2009; 37 (5): 941. DOI: 10.1016/j.jpainsymman.2003.06.004.
  40. Durand J., Deplanque G., Montheil V.et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial // Ann. Oncol. – 2012; 23 (1): 200–5. DOI: 10.1093/annonc/mdr045.
  41. Kus T., Aktas G., Alpak G., et al. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study // Support Care Cancer. – 2016; 24 (5): 2085–91. DOI: 10.1007/s00520-015-3009-x.
  42. Richards J., Bombardier C., Wilson C. et al. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial // Arch. Phys. Med. Rehabil. – 2015; 96 (4): 680–9. DOI:10.1016/j.apmr.2014.11.024.
  43. Eardley W., Toth C. An openlabel, nonrandomized comparison of venlafaxine and gabapentin as monotherapyor adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy // J. Pain Res. – 2010; 3: 33–49.
  44. Sindrup S., Bach F., Madsen C. et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial // Neurology. – 2003; 60 (8): 1284–9. DOI: 10.1212/01.WNL.0000058749.49264.BD.
  45. Zissis N., Harmoussi S., Vlaikidis N. et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache // Cephalalgia. – 2007; 27 (4): 315–24. DOI: 10.1111/j.1468-2982.2007.01300.x.
  46. Ozyalcin S., Talu G., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine // Headache. – 2005; 45 (2): 144–52. DOI: 10.1111/j.1526-4610.2005.05029.x.
  47. Bulut S., Berilgen M., Baran A. et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study // Clin. Neurol. Neurosurg. – 2004; 107 (1): 44–8. DOI: 10.1016/j.clineuro.2004.03.004.
  48. Lee H., Kim J., Min B. et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial // Am. J. Gastroenterol. – 2010; 105 (7): 1504–12. DOI: 10.1038/ajg.2010.82.
  49. Forssell H., Tasmuth T., Tenovuo O. et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial // J. Orofac. Pain. – 2004; 18 (2): 131–7.
  50. Dwight M., Arnold L., O'Brien H. et al. An open clinical trial of venlafaxine treatment of fibromyalgia // Psychosomatics. – 1998; 39 (1): 14–7. DOI: 10.1016/S0033-3182(98)71375-1.
  51. Diaz-Marsá M., Palomares N., Morón M. et al. Psychological factors affecting response to antidepressant drugs in fibromyalgia // Psychosomatics. – 2011; 52 (3): 237–44. DOI: 10.1016/j.psym.2010.12.014.
  52. Sayar K., Aksu G., Ak I. et al. Venlafaxine treatment of fibromyalgia // Ann. Pharmacother. – 2003; 37 (11): 1561–5. DOI: 10.1345/aph.1D112.
  53. Zijlstra T., Barendregt P., van De Laar M. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial // Arthritis Rheum. – 2002; 46: S105.
  54. Moulin D., Boulanger A., Clark A. et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society // Pain Res. Manag. – 2014; 19 (6): 328–35. DOI: 10.1155/2014/754693.
  55. Gharibian D., Polzin J., Rho J. Compliance and persistence of antidepressants versus anticonvulsants in patients with neuropathic pain during the first year of therapy // Clin. J. Pain. – 2013; 29 (5): 377–81. DOI: 10.1097/AJP.0b013e31825e45d9.